Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Aravive Inc (ARAV)

Aravive Inc (ARAV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 83,270
  • Shares Outstanding, K 20,714
  • Annual Sales, $ 5,690 K
  • Annual Income, $ -30,540 K
  • 60-Month Beta 3.10
  • Price/Sales 14.90
  • Price/Cash Flow N/A
  • Price/Book 1.34
Trade ARAV with:

Options Overview Details

View History
  • Implied Volatility 58.61%
  • Historical Volatility 42.18%
  • IV Percentile 2%
  • IV Rank 7.43%
  • IV High 295.73% on 10/06/20
  • IV Low 39.59% on 09/01/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 34
  • Volume Avg (30-Day) 40
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 170
  • Open Int (30-Day) 272

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.42
  • Number of Estimates 3
  • High Estimate -0.41
  • Low Estimate -0.43
  • Prior Year -0.66
  • Growth Rate Est. (year over year) +36.36%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.77 +6.63%
on 09/14/21
4.40 -8.63%
on 08/31/21
-0.04 (-0.99%)
since 08/24/21
3-Month
3.63 +10.74%
on 08/19/21
5.98 -32.78%
on 06/30/21
-1.58 (-28.21%)
since 06/24/21
52-Week
3.63 +10.74%
on 08/19/21
9.95 -59.60%
on 03/19/21
-0.92 (-18.62%)
since 09/24/20

Most Recent Stories

More News
Aravive to Participate in Fireside Chat at Cantor Fitzgerald Virtual Global Healthcare Conference

Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer...

ARAV : 4.02 (-1.71%)
3 Biotech Stocks Wall Street Predicts Will Rally by More Than 170%

The rapid spread of the COVID-19 Delta variant is fostering renewed investor interest in the biotech industry. Also, with the increasing demand for treatments for other critical diseases, the industry...

ASLN : 3.25 (+0.31%)
AQST : 4.33 (-3.56%)
ARAV : 4.02 (-1.71%)
Thinking about buying stock in Aravive, Marin Software, Staffing 360 Solutions, Corbus Pharmaceuticals, or Globalstar?

/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ARAV, MRIN, STAF, CRBP, and GSAT.

GSAT : 1.6800 (-5.62%)
STAF : 2.07 (-3.72%)
ARAV : 4.02 (-1.71%)
CRBP : 1.0400 (-5.45%)
MRIN : 10.21 (+19.56%)
Aravive (ARAV) Reports Q1 Loss, Lags Revenue Estimates

Aravive (ARAV) delivered earnings and revenue surprises of 2.22% and -54.69%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

ARAV : 4.02 (-1.71%)
Aravive Announces Board Member Transition to Advisory Role

Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that Dr. Ray Tabibiazar will be stepping down from the Aravive Board of Directors...

VSAR : 1.19 (-1.65%)
ARAV : 4.02 (-1.71%)
Aravive Announces Phase 3 Trial Design for AVB-500 in Platinum Resistant Ovarian Cancer

Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced the Company has received guidance from the U.S. Food and Drug Administration (FDA)...

ARAV : 4.02 (-1.71%)
Aravive to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced the Company will present and conduct one-on-one meetings with investors at the Piper...

ARAV : 4.02 (-1.71%)
Aravive to Host Virtual Expert Event Focused on Ovarian and Renal Cancer on November 20, 2020

Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced the Company will host a virtual Ovarian and Renal Cancer Expert Event on Friday,...

ARAV : 4.02 (-1.71%)
Aravive and 3D Medicines Announce Strategic Collaboration to Develop and Commercialize AVB-500 in Greater China

Aravive to Receive $12 Million Signing Payment, up to an Additional $207 Million in Future Milestone Payments plus Tiered Royalties

ARAV : 4.02 (-1.71%)
Aravive Reports Third Quarter 2020 Financial Results and Provides Corporate Updates

-- Company expects to initiate pivotal trial of AVB-500 in Platinum Resistant Ovarian Cancer during fourth quarter 2020/first quarter 2021, based on Phase 1b results

ARAV : 4.02 (-1.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Aravive Inc. is a biotechnology company. It develops therapeutic proteins for the treatment of metabolic diseases and endocrine disorders. Aravive Inc. is based in TX, United States.

See More

Key Turning Points

3rd Resistance Point 4.22
2nd Resistance Point 4.17
1st Resistance Point 4.09
Last Price 4.02
1st Support Level 3.96
2nd Support Level 3.91
3rd Support Level 3.83

See More

52-Week High 9.95
Fibonacci 61.8% 7.54
Fibonacci 50% 6.79
Fibonacci 38.2% 6.04
Last Price 4.02
52-Week Low 3.63

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar